Pelage Pharmaceuticals, Inc. is a biotechnology company developing novel drugs to promote hair health.
Market:
Currently, 400 million people, both men and women, suffer from Alopecia worldwide. There are only two FDA-approved medications for treating non-scarring Alopecia, Propecia and Rogaine (Minoxidil). Propecia is associated with adverse side effects and neither drug is very effective. More than $7 billion is being spent on hair loss treatments annually.
Technology:
Pelage’s proprietary small molecules are the first to target hair follicle stem cell metabolism causing their activation.Advantages:
- Activates quiescent hair follicle stem cells
- Small molecules access the hair follicles when applied to the scalp
- No need for implants, injections or oral treatments
Patents:
- Pelage has licensed rights from the University of California to licensed patents covering the technology.
Development Stage:
- Clinical
Select Publications:
Contact:
Email: info@pelagepharma.comPortfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.